ライフサイエンスコーパス: second-line

1 who received bevacizumab at crossover or as second line.

2 Second-line (2 L) chemotherapies for advanced or metasta

3 of checkpoint inhibitors in the treatment of second-line advanced NSCLC.

4 of sarcoidosis were less likely to require a second-line agent (4.3% vs. 16.2%, P = 0.011).

5 ed by the competitive inhibitor reserpine, a second-line agent to treat hypertension, and by the nonc

6 ommended dosages vary widely, and first- and second-line agents are designated in only 18 and 2 state

7 (SGLT2) inhibitors are increasingly used as second-line agents, direct comparisons between these tre

8 teral sensitivities, and then using these as second-line agents.

9 or that would extend the currently available second-line agents.

10 atic germ cell tumor (GCT) can be cured with second-line and even third-line regimens.

11 fourth line or greater) to 19.4% (n = 6/31; second line) and median progression-free survival rangin

12 ts first line), ramucirumab (anti-angiogenic second line), and nivolumab or pembrolizumab (anti-PD-1

13 es (18%), including 3% of first-line, 18% of second-line, and 31% of third- or greater line samples.

14 Patients who had received second-line androgen deprivation therapy (ADT) or chemot

15 e updated in 2019 with a reclassification of second line anti-tuberculosis drugs.

16 es that confer resistance to both first- and second-line anti-TB drugs.

17 e detection of resistance to both first- and second-line anti-TB drugs.

18 action differs from those of most first- and second-line anti-tubercular drugs.

19 tive AR signaling and will respond to potent second-line antiandrogen therapies, including bicalutami

20 Eleven of the 14 had prior second-line antiandrogen treatment with abiraterone or e

21 ing number of strains fail to respond to the second-line antibiotic azithromycin(3).

22 Combining EV76-immunization and second-line antibiotic treatment, which are individually

23 ng energy metabolism and classical first and second line antibiotics must be considered to maximize t

24 Data on the number of patients who received second-line anticancer treatment and the occurrence of o

25 lternative to phenytoin as the first-choice, second-line anticonvulsant in the treatment of paediatri

26 ong patients initiating treatment with other second-line antidiabetic medications.

27 Second-line antiretroviral therapy (ART) based on ritona

28 ot well defined among individuals on failing second-line antiretroviral therapy (ART) in low- and mid

29 For second-line antiretroviral therapy, WHO recommends a boo

30 or ritonavir-boosted lopinavir plus NRTI for second-line antiretroviral therapy.

31 that reduces the efficacy of ethionamide, a second-line antitubercular drug used to combat multidrug

32 utations to predict resistance to first- and second-line antituberculosis drugs and validated our pre

33 d pelvic floor rehabilitation represented a "second line" approach.

34 a published open-label, randomised trial of second-line ART (EARNEST) in sub-Saharan Africa.

35 2.6, 95% CI 2.5-2.8; p<0.0001) and switch to second-line ART (HR 5.2, 4.4-6.1; p<0.0001]) compared wi

36 Overall, 67 (6%) switched to second-line ART and 54 (4%) died.

37 cohort A (no lopinavir resistance) stayed on second-line ART and cohorts B (B1, best available nucleo

38 Adaptive VL achieved an ICER <1x GDP if second-line ART and VL costs simultaneously decreased to

39 ry by 25 percentage points, and switching to second-line ART by 1 percentage point compared with stan

40 ot well-defined among individuals on failing second-line ART in low- and middle-income countries (LMI

41 f confirmed virological failure, a switch to second-line ART is indicated.

42 Second-line ART regimens were based on ritonavir-boosted

43 The incidence of VF on second-line ART was 12.9 per 100 person-years (n = 23),

44 7 644 received first-line ART, 1476 received second-line ART, and 1810 received both.

45 Virological suppression, switch to second-line ART, death, and loss to follow-up were analy

46 re than 24 weeks of protease inhibitor-based second-line ART.

47 T and 101 weeks (IQR 51-178) for patients on second-line ART.

48 ct NRTI activity in protease inhibitor-based second-line ART.

49 ment of >/=1000 copies per mL) and switch to second-line ART.

50 ghting the value of viral load monitoring of second-line ART.

51 he risk of virological failure and switch to second-line ART.

52 n retention, and no viral load monitoring or second-line ART.

53 rected to prescribe protease inhibitor-based second-line ART.

54 luded if they received >180 days of PI-based second-line ART.

55 We assessed drug survival of second-line biologic therapies and estimated the risk of

56 Little is known about the drug survival of second-line biologic therapies for psoriasis in routine

57 pport clinical decision making when choosing second-line biologic therapy for patients with psoriasis

58 Area and Severity Index at switching to the second-line biologic therapy were predictors of overall

59 -based regimens and reduced use of expensive second-line boosted protease inhibitor regimens, this po

60 hibition with gemcitabine (Gem), a first- or second-line chemotherapeutic agent for PDAC treatment.

61 Patients receiving second-line chemotherapy followed by resection had signi

62 Patients undergoing second-line chemotherapy followed by resection have a po

63 emoglobin </= 11.0 g/dL, receiving first- or second-line chemotherapy for metastatic breast cancer, w

64 to endorse the remaining recommendations for second-line chemotherapy, as well as other recommendatio

65 the phase 3 PROMISE-meso trial compared with second-line chemotherapy.

66 ide reverse-transcriptase inhibitors (NRTIs) second-line combination after 144 weeks of follow-up in

67 inhibitor plus raltegravir as an alternative second-line combination.

68 nger is burnt), the resulting pain invokes a second-line coping response-such as licking the injured

69 biologic therapies and decreased over time; second-line discontinuation because of adverse events wa

70 [81%]) and one-third had resistance to >/=1 second-line drug (24/73 tested).

71 n be considered as a potential first-choice, second-line drug for benzodiazepine-refractory status ep

72 re ineligible for the new regimen because of second-line drug resistance, we projected a change in in

73 to expand treatment access, and the role of second-line drug resistance.

74 to expand treatment access, and the role of second-line drug resistance.

75 Recommendations for first-line and second-line drug testing and organism group, specific me

76 on-recommended 5-drug regimen while awaiting second-line drug-susceptibility test (DST) results.

77 r drug susceptibility test of first-line and second-line drugs at diagnosis is required to improve ou

78 ority of phenotypic resistance to first- and second-line drugs in MDR and XDR-TB.

79 sonnei to develop resistance to alternative second-line drugs may further limit future treatment opt

80 nd optimal treatment, particularly for toxic second-line drugs such as D-cycloserine.

81 : what subset of patients might benefit from second-line drugs, how to choose an optimal second-line

82 nes conferring resistance to other first and second-line drugs, including in pncA (pyrazinamide), emb

83 for first-line drugs and 32 days sooner for second-line drugs.

84 hat required extended therapy and the use of second-line drugs.

85 erculosis using tailored regimens containing second-line drugs.

86 s susceptible by line-probe assays (LPAs) to second-line drugs.

87 -tuberculosis patients, only 44.7% (596) had second-line DST for both fluoroquinolones and second-lin

88 We quantified the second-line DST results time and proportion of patients

89 time from specimen collection to phenotypic second-line DST results.

90 Median time to second-line DST was 53 days (range, 8-259).

91 Of the 252 patients with complete second-line DST, 101 (40.1%) potentially initiated a sub

92 The second line expresses APP(KM670/671NL)/PSEN1(Deltaexon9)

93 Data on second-line failure and development of protease inhibito

94 e III study reported a survival benefit with second-line fluorouracil (FU) and oxaliplatin using the

95 state cancer, with no more than two previous second-line hormonal therapies, and a castrate concentra

96 gen deprivation therapy, most men respond to second-line hormonal therapies.

97 Second-line hormonal therapy (eg, antiandrogens, CYP17 i

98 This PCO addresses second-line hormonal therapy for chemotherapy-naive men

99 However, guidelines have neither addressed second-line hormonal therapy for nonmetastatic CRPC nor

100 ation of pretest probability with first- and second-line immunoassays for anti-PF4/heparin antibodies

101 bability and likelihood ratios of first- and second-line immunoassays.

102 lure of treatment with corticosteroids and a second-line immunosuppression drug and treated with biol

103 lure of treatment with corticosteroids and a second-line immunosuppression drug experienced satisfact

104 5% required oral steroids and 13.8% required second-line immunosuppression.

105 Forty-five (61%) patients received second-line immunotherapy (cyclophosphamide, rituximab,

106 rio analysis where ibrutinib was used in the second-line in the delayed ibrutinib arm, first-line ibr

107 lgesic (49.1% of patients); opiates are the "second line" in 31.5% of patients; however, 33% patients

108 A second line included these 17 putative sites plus the fi

109 Bedaquiline is used as a substitute for second-line injectable (SLI) intolerance in the treatmen

110 h resistance to both a fluoroquinolone and a second-line injectable (XDR).

111 least 5 likely effective drugs (including a second-line injectable and a fluoroquinolone) used for a

112 oroquinolone-resistant multidrug resistance, second-line injectable-resistant multidrug resistance, a

113 econd-line DST for both fluoroquinolones and second-line injectable: 55.8% (466 of 835) in the Wester

114 mycobacterials, including first-line agents, second-line injectables, fluoroquinolones, and World Hea

115 Phenytoin is the recommended second-line intravenous anticonvulsant for treatment of

116 cond-line IPI or first-line NIVO followed by second-line IPI are the most cost-effective, immune-base

117 ma, first-line PEM every 3 weeks followed by second-line IPI or first-line NIVO followed by second-li

118 Results PEM every 3 weeks followed by second-line IPI was both more effective and less costly

119 e analysis; 32% received T-DM1 as first- and second-line line therapy, and 48% received it as fourth-

120 nd safety of phenytoin and levetiracetam for second-line management of paediatric convulsive status e

121 nce supports alternatives to splenectomy for second-line management of patients with persistently low

122 Second, 6 second-line new agents have been recently developed and

123 s in patients with CRPC receiving first- and second-line NHT and, to the best of our knowledge, is th

124 ohort (and separately for the first-line and second-line NHT cohorts) were best for CTC- patients, in

125 1 through October 2015, 38 patients received second-line nintedanib plus docetaxel.

126 also separately examined the first-line and second-line novel hormonal therapy (NHT) settings.

127 culated the predicted activity of prescribed second-line NRTIs.

128 income settings for the purpose of selecting second-line NRTIs.

129 In addition, Tyr-92 was identified as a second line of defense to maintain the position of Phe-1

130 mensal IgG responses, which might serve as a second line of defense.

131 analyses of 37 orangutan genomes provided a second line of evidence.

132 e (5.4%) of 56 responded to docetaxel in the second line of therapy.

133 ths (fourth line or greater) to 10.7 months (second line), on the basis of investigator assessment, w

134 atment for tuberculosis, and preservation of second line options.

135 Maintenance therapy (second line or more) with single-agent PARPi may be offe

136 d rucaparib versus placebo after response to second-line or later platinum-based chemotherapy in pati

137 following a complete or partial response to second-line or later platinum-based chemotherapy.

138 Trials of nivolumab in the second-line or later setting with at least 4 years follo

139 ol-defined population (patients who received second-line or later treatment); safety was also assesse

140 tries and randomly assigned (1:1) to receive second-line oral buparlisib (100 mg once daily) or place

141 Second-line oral treatments recommended include an opioi

142 Safe, efficacious, second-line pharmacological treatment options exist for

143 Participants in cohort A remained on their second-line protease inhibitor, and had the most partici

144 e-Guerin therapy fails in >50% of cases, and second-line radical cystectomy is associated with overtr

145 tor with NRTIs remains the best standardised second-line regimen for use in programmes in resource-li

146 s not responsive to treatment or for which a second-line regimen had been discontinued because of sid

147 Susceptibility to at least one second-line regimen was preserved in 59%, as was suscept

148 Susceptibility to at least 1 second-line regimen was preserved in 59%, as were suscep

149 Susceptibility to a second-line regimen was significantly higher among women

150 Susceptibility to a second-line regimen was significantly higher among women

151 second-line drugs, how to choose an optimal second-line regimen, and their effects on quality of lif

152 Providing second-line regimens and shifting treatment providers to

153 nd middle-income countries increasingly need second-line regimens with boosted protease inhibitors.

154 ited the efficacy of standardized first- and second-line regimens.

155 own to significantly improve survival in the second-line setting after sorafenib failure.

156 inhibitor, can also improve survival in the second-line setting among patients with AFP>=400 ng/dL.

157 the patients treated with fulvestrant in the second-line setting and beyond (n=1552), the difference

158 motherapy in the neoadjuvant and adjuvant or second-line setting compared with more widely adopted re

159 he cost-effectiveness of cabozantinib in the second-line setting for patients with an advanced hepato

160 In the first-line or second-line setting, CDK4/6 inhibitors plus hormone ther

161 ials evaluating checkpoint inhibitors in the second-line setting, three of which were randomized tria

162 ncer, there is no established therapy in the second-line setting.

163 m(2) days 1, 8, and 15 every 28 days) in the second-line setting.

164 n the treatment of metastatic disease in the second-line setting.

165 of a planned interim analysis of a trial in second-line SQ NSCLC (CM017) that demonstrated an overal

166 ailable literature and discuss the potential second-line systemic therapy options for advanced biliar

167 Cabazitaxel is a second-line taxane chemotherapeutic agent that provides

168 out extrapulmonary TB, pregnancy, a previous second-line TB medication exposure, or drug resistance t

169 unresolved cases, ID-H/PF4-PaGIA was used as second-line testing (additional TAT, 30 minutes).

170 l lymphoma that is refractory to primary and second-line therapies or that has relapsed after stem-ce

171 Second-line therapies should be bismuth quadruple therap

172 with hepatocellular carcinoma, as first- and second-line therapies, and are awaiting approval by the

173 high-risk patients for closer monitoring and second-line therapies, as well as low-risk patients who

174 involves trimethoprim-sulfamethoxazole, with second-line therapies, including atovaquone, dapsone, an

175 t options are essential to selecting optimal second line therapy for patients whose disease progresse

176 AR drug may be used as an alternative second line therapy for treating HER2 + BC.

177 pe-Africa Research Network for Evaluation of Second-line Therapy (EARNEST) trial.

178 Ninety-two patients (35%) needed second-line therapy after a median of 49 months.

179 Patients with AL amyloidosis who need second-line therapy after response to up-front treatment

180 n of nivolumab + ipilimumab as an option for second-line therapy and third-line therapy is discussed.

181 by resistance testing, of the NRTIs used in second-line therapy and treatment outcomes for patients

182 31%; and (5) suboptimal response to ASCT and second-line therapy as consolidation, 4%.

183 ment has been accepted widely for the first-/second-line therapy for advanced gastric cancer (AGC).

184 etinib + docetaxel with docetaxel alone as a second-line therapy for advanced KRAS-mutant NSCLC.

185 view to update guideline recommendations for second-line therapy for metastatic pancreatic cancer.

186 r receptor 2, MET, and AXL and is a standard second-line therapy for metastatic renal cell carcinoma

187 reverse-transcriptase inhibitors (NRTIs) in second-line therapy for patients with HIV, but evidence

188 The drug also has been approved as second-line therapy for polycythemia vera (PV).

189 Lurbinectedin was active as second-line therapy for SCLC in terms of overall respons

190 tients with organ progression at the time of second-line therapy had inferior survival.

191 l survival versus placebo plus paclitaxel as second-line therapy in a phase 2 study in Asian patients

192 estigated in combination with doxorubicin as second-line therapy in a randomised phase 3 trial.

193 Hypoglossal nerve stimulation is a useful second-line therapy in patients who cannot tolerate cont

194 Purpose The standard of care for second-line therapy in patients with advanced pancreatic

195 maintenance therapy after chemotherapy-based second-line therapy in patients with chronic lymphocytic

196 ll be used in up to 2 million individuals as second-line therapy in sub Saharan Africa by 2020.

197 .8% of all patients who received any sort of second-line therapy in the TMZ arm.

198 b could be considered a standard of care for second-line therapy in this post-hydroxyurea patient pop

199 Survival and second-line therapy initiation were compared with an his

200 combination of ganetespib and docetaxel for second-line therapy of patients with advanced adenocarci

201 , had a shorter survival after initiation of second-line therapy on univariate, but not on multivaria

202 t-line therapy with sorafenib or lenvatinib, second-line therapy options for appropriate candidates i

203 The median time from ASCT to second-line therapy was 24.3 months.

204 hree hundred three patients received HDCT as second-line therapy with a 2-year PFS of 63% (95% CI, 57

205 + bev, and until better data are available, second-line therapy with a tyrosine kinase inhibitor may

206 We compared second-line therapy with high-dose chemotherapy and auto

207 rapy (with at least a partial response after second-line therapy); had received a purine analogue, be

208 Of 172 patients with known second-line therapy, 85 received CTx (49%); 70, ASCT (41

209 omisation was stratified by age, response to second-line therapy, and prognostic factors.

210 As second-line therapy, fulvestrant should be administered

211 For second-line therapy, gemcitabine plus NAB-paclitaxel sho

212 rved in 22% and 12% of patients who received second-line therapy, respectively.

213 As second-line therapy, splenectomy and Rituximab are both

214 otably, in patients receiving study drugs as second-line therapy, the mOS was 7.5 months.

215 ay influence clinician and patient choice of second-line therapy.

216 t-line therapy, or tramadol or duloxetine as second-line therapy.

217 cythaemia vera without splenomegaly who need second-line therapy.

218 delines that help in choosing an appropriate second-line therapy.

219 examethasone independently prolonged time to second-line therapy.

220 ming virological failure before switching to second-line therapy.

221 d Drug Administration of PD-1 inhibitors for second-line therapy.

222 ent treatment with nilotinib or dasatinib as second-line therapy.

223 ear or less, and progressive disease despite second-line therapy.

224 failure of these drugs; there is no approved second-line therapy.

225 irst-line setting and anetumab ravtansine as second-line therapy.

226 lecular mechanism of resistance and to guide second-line therapy.

227 ore effective than either alone and provides second line treatment for those with rhinitis poorly con

228 on (AF) has emerged as a widespread first or second line treatment option.

229 ulation (excluding those who did not require second-line treatment after randomisation and those who

230 stance can lead to long-term cost savings in second-line treatment and (ii) its higher sensitivity co

231 After exclusion of those who did not require second-line treatment and those who did not consent, 286

232 or metastatic urothelial carcinoma receiving second-line treatment and warrants further investigation

233 Responses to second-line treatment are uncommon.

234 al photopheresis (ECP) is considered a valid second-line treatment for acute and chronic graft versus

235 oint blockers have recently been approved as second-line treatment for advanced non-small-cell lung c

236 ated with endocrine therapy as first-line or second-line treatment for hormone receptor-positive, HER

237 nib is an oral angiokinase inhibitor used as second-line treatment for non-small cell lung cancer.

238 nation with paclitaxel could be an effective second-line treatment for patients with platinum-pretrea

239 US Food and Drug Administration in 2016 as a second-line treatment for patients with primary biliary

240 and it is now considered standard of care as second-line treatment for patients with recurrent/refrac

241 al impact and cost-effectiveness of OCA as a second-line treatment for PBC in combination with ursode

242 ment initiation and loss to follow-up before second-line treatment for RR-TB across South Africa.

243 l photopheresis is confirmed as an effective second-line treatment in both aGVHD and cGVHD, because i

244 Regarding second-line treatment in patients who received first-lin

245 pective cohort study was conducted to assess second-line treatment initiation and treatment delay amo

246 bout the functional relationship of delaying second-line treatment initiation for human immunodeficie

247 ivation rates remain above 30%, and standard second-line treatment is yet to be established.

248 Radiotherapy can be used as a second-line treatment modality.

249 abozantinib with best supportive care in the second-line treatment of advanced hepatocellular carcino

250 alone might be appropriate for first-line or second-line treatment of hormone receptor-positive, HER2

251 added to systemic therapy in the first- and second-line treatment of patients with colorectal liver

252 d, for several decades, there was no optimal second-line treatment of patients with corticosteroid-re

253 ce exists to support the use of nivolumab as second-line treatment of patients with squamous advanced

254 have greater efficacy than paclitaxel in the second-line treatment of urothelial cancers.

255 antitumour activity and is a first-line and second-line treatment option for patients with programme

256 arcinoma, and might represent a new standard second-line treatment option for these patients.

257 Doubts exist regarding optimal second-line treatment options for HIV-1-infected patient

258 udied and several advances in first-line and second-line treatment options should yield significant i

259 shed, traditional therapies as first-line or second-line treatment options.

260 e intervals between last treatment cycle and second-line treatment point towards clinical progression

261 We observed that splenectomy for ITP second-line treatment was more effective than Rituximab

262 cin or levofloxacin within triple therapy as second-line treatment were associated with greater effec

263 (excluded patients who died without starting second-line treatment) were evaluated.

264 Of 450 patients (39%) who received second-line treatment, 194 received HMAs, 148 received L

265 with convulsive status epilepticus requiring second-line treatment, were randomly assigned (1:1) usin

266 ffectiveness than bismuth-based therapy as a second-line treatment, while bismuth-based therapy achie

267 and can be considered a suitable option for second-line treatment.

268 of 289 patients died without progressing to second-line treatment.

269 med RR-TB and those reported to have started second-line treatment.

270 sitive PD-L1 staining, received nivolumab as second-line treatment.

271 l cancer who may benefit from gefitinib as a second-line treatment.

272 order of hormonal therapies for CRPC beyond second-line treatment.

273 e treatment and rituximab-based regimens for second-line treatment.

274 reduced sensitivity, and foregone savings in second-line treatment.

275 6 Italian centers, were submitted to ECP for second-line treatment.

276 ll consecutive patients who underwent an ITP second-line treatment: Rituximab or splenectomy.

277 hlorambucil, or alemtuzumab as first-line or second-line treatment; and had an Eastern Cooperative On

278 ed with ESAs, none of the most commonly used second-line treatments (HMA and LEN) significantly impro

279 that ruxolitinib is not superior to current second-line treatments for ET.

280 ive analysis of early response to first- and second-line treatments in 127 patients with classic HL w

281 lusion: The findings support that first- and second-line treatments in HL do not require different re

282 ines Agency-should be preferentially used as second-line treatments in these patient populations, typ

283 ecomes more common, especially as first- and second-line treatments, immunotoxicity and autoimmunity

284 Second-line treatments, including hypomethylating agents

285 Because first-line or second-line treatments, or both, based on chemotherapy a

286 without targeted therapies as first-line or second-line treatments, or both, in postmenopausal women

287 ies plus targeted therapies as first-line or second-line treatments, or in both settings, in women wi

288 ves should be used (prescribed) as first- or second-line treatments, though a consensus agreed that b

289 matically analyze the response to first- and second-line treatments.

290 outcome after ESA failure and the effect of second-line treatments.

291 al patients responded variably to first- and second-line treatments.

292 rding which patients will benefit from which second-line treatments.

293 Therefore, we correlated MICs of first- and second-line tuberculosis drugs with time to sputum cultu

294 hole-genome sequencing, encode resistance to second-line tuberculosis drugs.

295 amide (PZA) is a key component of first- and second-line tuberculosis treatment regimens, there is no

296 de (PZA) is an antibiotic used in first- and second-line tuberculosis treatment regimens.

297 ER of $9 810 360 per QALY when compared with second-line use.

298 Second-line VF was frequent in this setting.

299 ove adherence in individuals presenting with second-line viral failure.

300 us (low risk vs high risk), line of therapy (second line vs third line), and anatomic site (pleural v